Information regarding Kerendia sales specifically for the year 2024 is not yet available as the year is ongoing. Drug sales data is typically reported retrospectively by pharmaceutical companies in quarterly and annual financial reports.
How did Kerendia perform in previous sales periods?
In the first quarter of 2024, Bayer reported net sales for Kerendia of €211 million (approximately $227 million USD). This represents a 7% increase compared to the same period in 2023 [1]. For the full year 2023, Kerendia achieved sales of €787 million (approximately $848 million USD) [2].
When does Kerendia's patent protection expire?
The patent protection timeline for Kerendia (finerenone) can be complex, involving multiple patents covering different aspects of the drug, such as the compound itself, its formulation, and its method of use. Generally, the compound patent for finerenone is expected to expire in the mid-2030s, but specific expiry dates can vary by region and are subject to potential extensions or challenges [3]. Information on specific patent expiry dates and related exclusivity periods can be found on DrugPatentWatch.com [4].
Who manufactures Kerendia?
Kerendia is manufactured by Bayer [1].
What is Kerendia used for?
Kerendia is a non-steroidal, selective mineralocorticoid receptor antagonist. It is indicated to reduce the risk of sustained decrease in estimated glomerular filtration rate (eGFR), kidney failure, kidney death, cardiovascular death, non-fatal myocardial infarction, and stroke in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes [1].